<SEC-DOCUMENT>0001566044-21-000024.txt : 20210506
<SEC-HEADER>0001566044-21-000024.hdr.sgml : 20210506
<ACCEPTANCE-DATETIME>20210506071047
ACCESSION NUMBER:		0001566044-21-000024
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20210506
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210506
DATE AS OF CHANGE:		20210506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VYNE Therapeutics Inc.
		CENTRAL INDEX KEY:			0001566044
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				453757789
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38356
		FILM NUMBER:		21895752

	BUSINESS ADDRESS:	
		STREET 1:		520 U.S. HIGHWAY 22, SUITE 204
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		800-775-7936

	MAIL ADDRESS:	
		STREET 1:		520 U.S. HIGHWAY 22, SUITE 204
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Menlo Therapeutics Inc.
		DATE OF NAME CHANGE:	20180201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Menlo Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170728

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tigercat Pharma, Inc.
		DATE OF NAME CHANGE:	20130104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mnlo-20210506.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:56529dd1-5759-46c4-b2ac-a07bf551e378,g:904f905f-39e0-450c-8019-d0e9182565ac,d:00feedac202d479c8149ec5d91684529--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mnlo-20210506</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV80L2ZyYWc6MzU5Yjc2NzhlNWE4NGRhN2I0NzlmODliNTFhNmI4MWMvdGFibGU6YmFlNzEwMjVjNjUyNGNmNWFjMjQwNzVlMTg2Zjg5NTYvdGFibGVyYW5nZTpiYWU3MTAyNWM2NTI0Y2Y1YWMyNDA3NWUxODZmODk1Nl8wLTEtMS0xLTA_6570c9cd-5c02-437e-8881-3abc21ab68e8">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV80L2ZyYWc6MzU5Yjc2NzhlNWE4NGRhN2I0NzlmODliNTFhNmI4MWMvdGFibGU6YmFlNzEwMjVjNjUyNGNmNWFjMjQwNzVlMTg2Zjg5NTYvdGFibGVyYW5nZTpiYWU3MTAyNWM2NTI0Y2Y1YWMyNDA3NWUxODZmODk1Nl8xLTEtMS0xLTA_8193b06b-ae45-4276-b83a-ee4ef1a3c8aa">0001566044</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mnlo-20210506.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-06</xbrli:startDate><xbrli:endDate>2021-05-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i00feedac202d479c8149ec5d91684529_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:2pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODA1_07b8748a-e245-42b2-bf4b-b94f717e0874">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________________________________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported) <ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF80NDA_2b2e56bd-3459-4091-ad08-184bf7cf4e14">May&#160;6, 2021</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xNzk4_461e8cdf-fef4-432d-ac03-523cffa12b9d">VYNE Therapeutics Inc</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________________________________________________________________________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6NGU2Mjc3NmY0OTQyNGUxMmFlMGYzOTU4MzgwNzg1N2MvdGFibGVyYW5nZTo0ZTYyNzc2ZjQ5NDI0ZTEyYWUwZjM5NTgzODA3ODU3Y18wLTAtMS0xLTA_40b8fbee-1dce-43f5-b4ea-8e9df114659a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6NGU2Mjc3NmY0OTQyNGUxMmFlMGYzOTU4MzgwNzg1N2MvdGFibGVyYW5nZTo0ZTYyNzc2ZjQ5NDI0ZTEyYWUwZjM5NTgzODA3ODU3Y18wLTEtMS0xLTA_7632c04f-5b0c-4820-83c8-61c15c660bfe">001-38356</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6NGU2Mjc3NmY0OTQyNGUxMmFlMGYzOTU4MzgwNzg1N2MvdGFibGVyYW5nZTo0ZTYyNzc2ZjQ5NDI0ZTEyYWUwZjM5NTgzODA3ODU3Y18wLTItMS0xLTA_92d7f462-c72a-415f-947e-504473fa0426">45-3757789</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IRS Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODA2_3df3d713-fa8b-4fa6-9908-4bda7907e830">520 U.S. Highway 22, Suite 204</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xNzk5_67553aed-da69-4bb7-8ef7-0d45fede1fde">Bridgewater</ix:nonNumeric>, <ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODAw_f7583db5-fd68-4f14-97a0-9e2bf40dba97">New Jersey</ix:nonNumeric> <ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODA3_6fc95c90-75fd-4479-a4e8-2f060686779e">08807</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices, including Zip Code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODAx_15ffd636-c916-4d03-bb42-90726cb8bf91">800</ix:nonNumeric>) <ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODAy_8cdd7185-3568-4e99-bfa3-7c3a296097e0">775-7936</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________________________________________________________________________</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K&#160;filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6YjU2ZGRkYWJlYzE2NDkwMWIxODBlNDY1ZTIzNzAzZjgvdGFibGVyYW5nZTpiNTZkZGRhYmVjMTY0OTAxYjE4MGU0NjVlMjM3MDNmOF8wLTEtMS0xLTA_2f4e0088-ba3d-40e8-9d48-d3ceb1686c15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6YjU2ZGRkYWJlYzE2NDkwMWIxODBlNDY1ZTIzNzAzZjgvdGFibGVyYW5nZTpiNTZkZGRhYmVjMTY0OTAxYjE4MGU0NjVlMjM3MDNmOF8yLTEtMS0xLTA_224454f6-82e9-439e-88d7-cf2c5f7da4b1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12&#160;under the Exchange Act (17 CFR&#160;240.14a-12)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6YjU2ZGRkYWJlYzE2NDkwMWIxODBlNDY1ZTIzNzAzZjgvdGFibGVyYW5nZTpiNTZkZGRhYmVjMTY0OTAxYjE4MGU0NjVlMjM3MDNmOF80LTEtMS0xLTA_5cdb1466-ca39-481e-96a3-9b0cab5fb4d1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement&#160;communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR&#160;240.14d-2(b))</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6YjU2ZGRkYWJlYzE2NDkwMWIxODBlNDY1ZTIzNzAzZjgvdGFibGVyYW5nZTpiNTZkZGRhYmVjMTY0OTAxYjE4MGU0NjVlMjM3MDNmOF82LTEtMS0xLTA_383bfa52-f5d1-4a02-a25f-bad369599a88">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement&#160;communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR&#160;240.13e-4(c))</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.066%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6MDNjOTgxMmU3ODgxNGQ1ZDhkMjU1NTcxN2Y0OTFjMWEvdGFibGVyYW5nZTowM2M5ODEyZTc4ODE0ZDVkOGQyNTU1NzE3ZjQ5MWMxYV8xLTAtMS0xLTA_7504efec-1468-4cb1-a8a5-8879c7b291ad">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6MDNjOTgxMmU3ODgxNGQ1ZDhkMjU1NTcxN2Y0OTFjMWEvdGFibGVyYW5nZTowM2M5ODEyZTc4ODE0ZDVkOGQyNTU1NzE3ZjQ5MWMxYV8xLTItMS0xLTA_937191c1-096a-466d-891e-5a9de2965788">VYNE</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6MDNjOTgxMmU3ODgxNGQ1ZDhkMjU1NTcxN2Y0OTFjMWEvdGFibGVyYW5nZTowM2M5ODEyZTc4ODE0ZDVkOGQyNTU1NzE3ZjQ5MWMxYV8xLTQtMS0xLTA_ee7f2207-fea9-4615-91f7-168b827c3fd8">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934&#160;(&#167;240.12b-2&#160;of this chapter). Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODA4_2629dcfb-9712-40da-8338-98577d9171b3">&#9746;</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODAz_efc43d24-85f7-4391-86a1-544db63dc1bd">&#9746;</ix:nonNumeric></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i00feedac202d479c8149ec5d91684529_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;6, 2021, VYNE Therapeutics Inc. issued a press release announcing its financial results for the quarter ended March 31, 2021. The press release is being furnished as Exhibit 99.1.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in Item 2.02 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div id="i00feedac202d479c8149ec5d91684529_10"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d) Exhibits</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibit is being furnished herewith.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.257%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vyne-2021506q1x2021exx991.htm">Press release, dated May 6, 2021.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i00feedac202d479c8149ec5d91684529_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VYNE THERAPEUTICS INC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: <ix:nonNumeric contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xMy9mcmFnOjczNWQ5NjI4NTI0ODRlNjQ4NmExYjA5ZjA5ZjBiMmFiL3RhYmxlOjdiNzU1NjM1ODE1NDQxZjFiYzIzM2MwYmY3ZTAyNjE1L3RhYmxlcmFuZ2U6N2I3NTU2MzU4MTU0NDFmMWJjMjMzYzBiZjdlMDI2MTVfMi0wLTEtMS0w_2b2e56bd-3459-4091-ad08-184bf7cf4e14">May 6, 2021</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Mutya Harsch</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mutya Harsch<br/>Chief Legal Officer and General Counsel</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>vyne-2021506q1x2021exx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6c0fd19f510f41d2bf51ccdb6de7c099_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><img alt="image1.jpg" src="image1.jpg" style="height:75px;margin-bottom:5pt;vertical-align:text-bottom;width:274px"></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conference call and live webcast today at 8&#58;30 am Eastern Time</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">BRIDGEWATER, N.J., May 6, 2021  -- VYNE Therapeutics Inc. (Nasdaq&#58; VYNE) (&#8220;VYNE&#8221; or the &#8220;Company&#8221;) today announced financial results for the first quarter ended March&#160;31, 2021 and provided a corporate update.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Our sales organization continues to drive utilization of AMZEEQ and ZILXI, with prescriptions for both products gaining momentum,&#8221; said David Domzalski, Chief Executive Officer of VYNE Therapeutics.  &#8220;During the first quarter, we unveiled our newest candidate FMX114, a combination topical gel product candidate for the treatment of mild-to-moderate atopic dermatitis. We plan to take FMX114 into a Phase 2a study in the third quarter, with top-line results expected before year end.&#8221;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Quarter and Recent Highlights&#58;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA approved AMZEEQ&#174; (minocycline) label update to include new information indicating the low propensity of Propionibacterium acnes (more commonly known as &#8220;P. acnes&#8221;) to develop resistance to minocycline</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announced development program for FMX114, a combination topical gel for mild-to-moderate atopic dermatitis (AD)</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">FMX114 is a fixed combination of tofacitinib (pan-JAK inhibitor) and fingolimod (sphingosine 1-phosphate receptor modulator) designed to address the multi-factorial nature of AD </font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Phase 2a clinical study in AD expected to begin in 3Q 2021 with top-line results expected by year end</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Proof of concept demonstrated in an animal model of AD</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raised $73.1 million net proceeds from a registered direct offering of common stock and through utilization of an at-the-market equity offering program</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Executed 1-for-4 reverse stock split</font></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:68.824%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.937%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Performance<br>(in thousands, except per share amounts)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,119&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,550)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,233)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted Net Loss per Share</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.79)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Net Loss*</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,108)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,474)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Diluted Net Loss per Share*</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.62)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA*</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,024)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,346)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*  See &#34;Note Regarding the Use of Non-GAAP Financial Measures&#34; elsewhere in this earnings release.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Results for the First Quarter Ended March&#160;31, 2021</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues totaled $4.1 million for the three months ended March&#160;31, 2021 compared to $1.8 million for the three months ended March 31, 2020. For the three months ended March&#160;31, 2021, our revenue consisted of $3.9 million of product sales, and $0.2 million of royalty revenue. For the three months ended March&#160;31, 2020, revenues consisted solely of $1.8 million of product sales.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in product sales is due to the ZILXI product launch in October 2020 and increase in demand for AMZEEQ.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Goods Sold</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold was $0.6 million for the three months ended March&#160;31, 2021 compared to $0.3 million for the three months ended March 31, 2020. The increase in cost of goods sold is primarily due to an increase in sales volume.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross margin percentage was 85%&#160;for both the three months ended March&#160;31, 2021&#160;and March 31, 2020.  </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses for the three months ended March&#160;31, 2021 were $6.3 million, representing a decrease of $9.6 million, or 60.3%, compared to $16.0 million for the three months ended March&#160;31, 2020.  Employee-related expenses decreased $5.2 million primarily due to severance costs incurred in 2020 due to the merger with Foamix Pharmaceuticals Ltd. (the &#34;Merger&#34;).  Clinical trial and manufacturing expenses decreased with the completion of FCD 105 and serlopitant clinical trials and the product launches of AMZEEQ and ZILXI during 2020. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses for the three months ended March&#160;31, 2021 were $16.6 million, representing a decrease of $8.8 million, or 34.6%, compared to $25.4 million for the three months ended March&#160;31, 2020. Employee-related expenses decreased by $6.1 million primarily due to severance costs incurred in 2020 due to the Merger.   Professional services spend decreased as these expenses were incurred in 2020 as a result of the Merger.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total operating expenses adjusted for stock based compensation*</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below is a presentation of our total operating expenses for the three months ended March&#160;31, 2021, adjusted to exclude certain non-cash expenses incurred during the period. The adjustments below reflect non-cash expenses of stock based compensation.  We believe that the adjusted operating expenses are important measures as they better reflect the ongoing operations of the Company and exclude certain non-cash expenses.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:44.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.484%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reported for the three months ended March&#160;31, 2021</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted for the three months ended March&#160;31, 2021</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,333&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(458)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,875&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,616&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,984)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,632&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,949&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,442)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,507&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Adjusted results are non-GAAP financial measures.  See &#34;Note Regarding the Use of Non-GAAP Financial Measures&#34; elsewhere in this earnings release.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash &#38; Cash Equivalents</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, VYNE had cash, cash equivalents, restricted cash and investments of $120.4&#160;million. Cash used in operations was $12.6&#160;million.  We believe that our existing cash, cash equivalents and investments as of March 31, 2021 and projected cash flows from revenues will provide sufficient resources to fund its current ongoing needs for at least the next twelve months.  See VYNE&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 for additional discussion on liquidity.</font></div><div><font><br></font></div><div style="padding-left:9pt;text-indent:-9pt"><font><br></font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conference Call and Live Webcast</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VYNE management will host a conference call and live webcast today, Thursday, May 6, 2021, at 8&#58;30 am Eastern Time to discuss the financial results and provide a business update.</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:24.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Toll Free&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800-909-4985</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312-281-1211</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conference ID&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21993618</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Webcast&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;public.viavid.com&#47;index.php&#63;id&#61;144542</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A replay of the call will be archived on the Company&#8217;s website at www.vynetherapeutics.com promptly after the conference call.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note Regarding the Use of Non-GAAP Financial Measures</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided certain non-GAAP financial information as additional information to measure operating performance, including, among others, Adjusted Total Operating Expenses, Adjusted Net Loss, Adjusted Diluted Net Loss per Share and Adjusted EBITDA.  The Company believes that its presentation of such non-GAAP measures provides useful </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information to management and investors regarding its financial condition and operations.  Specifically, these measures exclude, among other things, share-based compensation.  The Company does not believe that such expenses accurately reflect the Company's ongoing operations, and the Company does not expect to incur similar expenses in future periods.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) and may be different from similarly titled non-GAAP measures reported by other companies. The Company has provided required reconciliations to the most comparable GAAP measures elsewhere in the document.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ZILXI and AMZEEQ Important Safety Information</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indications</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZILXI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (minocycline)  topical foam, 1.5% is for the treatment of adults with pimples and bumps caused by a condition called rosacea.  It is not known if ZILXI is safe and effective in children. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMZEEQ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (minocycline)  topical foam, 4%  is for the treatment of pimples and red bumps (non-nodular inflammatory lesions) that happen with moderate to severe acne in patients 9 years age and older.  It is not known if AMZEEQ is safe and effective in children under 9 years of age.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZILXI and AMZEEQ are both topical forms of the antibiotic minocycline and are available by prescription only. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ZILXI and AMZEEQ are for use on skin only (topical use). ZILXI and AMZEEQ are not for use in the mouth, eyes or vagina.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZILXI and AMZEEQ should not be used for the treatment of infections.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Important Safety Information</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ZILXI or AMZEEQ should not be used in people who are allergic to ZILXI, AMZEEQ, or any tetracycline medicine. Use of ZILXI or AMZEEQ should be stopped right away if a rash or other allergic symptom occurs.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ZILXI or AMZEEQ should not be used in women who are pregnant, may become pregnant or are nursing. If a woman becomes pregnant while using ZILXI or AMZEEQ, she should talk to her doctor. Tetracycline medicine when taken by mouth during pregnancy, infancy and&#47;or childhood up to the age of 8 years may permanently discolor teeth (yellow-gray-brown) and may slow the growth of bones. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ZILXI and AMZEEQ are flammable and fire, flame, and smoking must be avoided when applying and right after applying ZILXI or AMZEEQ. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">People should protect their skin from the sun while using ZILXI or AMZEEQ and avoid sunlight or artificial sunlight such as sunlamps or tanning beds. Use of ZILXI or AMZEEQ should be stopped if skin is sunburned. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">When taken by mouth, minocycline may cause feelings of lightheadedness, dizziness or spinning. People should not drive or operate dangerous machinery if they have these symptoms.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZILXI and AMZEEQ are both topical foams that contain minocycline, a tetracycline medicine. They are not taken by mouth.  However, tetracyclines, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">when taken by mouth (capsules or tablets)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, may cause serious side effects, including&#58; diarrhea which may be caused by an infection and cause watery or bloody stools&#59;  loss of appetite&#59; tiredness&#59; yellowing of the skin or eyes (jaundice)&#59; bleeding more easily than normal&#59; confusion&#59; sleepiness&#59;  vision changes, including blurred vision, double vision, or permanent vision loss&#59; unusual headaches&#59; fever&#59; rash&#59; joint pain&#59; body weakness&#59; discoloration or darkening of the skin, scars, teeth, or gums. People should call their doctor right away if these side effects occur.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most common side effect of ZILXI is diarrhea.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most common side effect of AMZEEQ is headache.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These are not all of the possible side effects for ZILXI or AMZEEQ. People should contact their doctor for medical advice about side effects and be sure to tell their doctor about all of their medical conditions and medicines they take before using ZILXI or AMZEEQ. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">People are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov&#47;medwatch or call 1-800-FDA-1088.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see full Prescribing Information for ZILXI and AMZEEQ.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About VYNE Therapeutics Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VYNE's mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its topical formulation capabilities, including its proprietary Molecule Stabilizing Technology (MST)&#8482;, and has received FDA approval for AMZEEQ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (minocycline) topical foam, 4%, and for ZILXI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (minocycline) topical foam, 1.5%.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information about our approved products, please see AMZEEQ&#8217;s Full Prescribing Information at AMZEEQ.com and ZILXI&#8217;s Full Prescribing Information at ZILXI.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE&#8217;s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Investor Relations&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Joyce Allaire</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LifeSci Advisors, LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">646-889-1200</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">jallaire&#64;lifesciadvisors.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Andrew Saik</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">VYNE Therapeutics</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">908-731-6180</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Andrew.Saik&#64;vynetx.com</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Statement Regarding Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the development and commercialization of VYNE&#8217;s products and product candidates, including FCD105 and FMX114, and other statements regarding the future expectations, plans and prospects of VYNE. All statements in this press release which are not historical facts are forward-looking statements. Any forward-looking statements are based on VYNE&#8217;s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to&#58; the COVID-19 pandemic and its impact on our business operations and liquidity, including our ability to progress a preclinical or clinical trial&#59; adverse events associated with the development and commercialization of our product candidates and approved products&#59; the outcome and cost of pre-clinical and clinical trials for current and future product candidates&#59; determination by the FDA that results from VYNE&#8217;s pre-clinical and clinical trials are not sufficient to support registration or marketing approval of product candidates&#59; the outcome of pricing, coverage and reimbursement negotiations with third party payors for AMZEEQ, ZILXI or any other products or product candidates that VYNE may commercialize in the future&#59; whether, and to what extent, third party payors impose additional requirements before approving AMZEEQ and ZILXI prescription reimbursement&#59; our ability to negotiate contracts with pharmacy benefit managers and other third-parties&#59; the eligible patient base and commercial potential of AMZEEQ, ZILXI or any of VYNE&#8217;s other products or product candidates&#59; risks of potential litigation by third-parties regarding infringement of third-party intellectual property&#59; risks that VYNE&#8217;s intellectual property rights, such as patents, may fail to provide adequate protection, may be challenged and one or more claims may be revoked or interpreted narrowly or will not be infringed&#59; risks that any of VYNE&#8217;s patents may be held to be narrowed, invalid or unenforceable or one or more of VYNE&#8217;s patent applications may not be granted and potential competitors may also seek to design around VYNE&#8217;s granted patents or patent applications&#59; additional competition in the acne and dermatology markets&#59; risks related to our indebtedness&#59; inability to raise additional capital on favorable terms or at all&#59; VYNE&#8217;s ability to recruit and retain key employees&#59; volatility in our stock price may result in rapid and substantial increases or decreases in our stock price that may or may not be related to our operating performance or prospects&#59; and VYNE&#8217;s ability to stay in compliance with applicable laws, rules and regulations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause VYNE&#8217;s actual results to differ from those contained in the forward-looking statements, see the section titled &#8220;Risk Factors&#8221; in VYNE&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, as well as discussions of potential risks, uncertainties, and other important factors in VYNE&#8217;s subsequent filings with the U.S. Securities and Exchange Commission. Although VYNE believes these forward-looking statements are reasonable, they speak only as of the date of this announcement </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and VYNE undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events.</font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i6c0fd19f510f41d2bf51ccdb6de7c099_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VYNE THERAPEUTICS INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. dollars in thousands, except per share data)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,516&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,563&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net of allowances</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,755&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,819&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,872&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,591&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,092&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,404&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current Assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,117&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,259&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,407&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,118&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,345&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,171&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,742&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and shareholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,490&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,780&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,521&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,452&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,360&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current Liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,549&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,453&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for employee severance benefits</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,274&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,174&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,270&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,249&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' Equity&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock&#58; $0.0001 par value&#59; 20,000,000 shares authorized at March&#160;31, 2021 and December&#160;31, 2020, respectively&#59; no shares issued and outstanding at March&#160;31, 2021 and December&#160;31, 2020, respectively</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#58; $0.0001 par value&#59; 75,000,000 shares authorized at March&#160;31, 2021 and December&#160;31, 2020, respectively&#59; 51,386,596 and 43,205,221 shares issued and outstanding at March&#160;31, 2021 and December&#160;31, 2020, respectively</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679,642&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603,685&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(586,746)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566,196)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Shareholders' Equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,901&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,493&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities and Shareholders' Equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,171&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,742&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i6c0fd19f510f41d2bf51ccdb6de7c099_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VYNE THERAPEUTICS INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. dollars in thousands, except per share data)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,889&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,119&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost of goods sold</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Expenses&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,333&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,953&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,616&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,415&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Operating Expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,949&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,368&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Loss</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,431&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,889&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(723)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss Before Income Tax</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,550&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,233&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,550&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,233&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per share basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.79&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average shares outstanding - basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,868&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,627&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i6c0fd19f510f41d2bf51ccdb6de7c099_10"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VYNE THERAPEUTICS INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. dollars in thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Operating Activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Loss</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,550&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,233&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments required to reconcile net loss to net cash used in</font></div><div style="padding-left:24.75pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">operating activities&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in marketable securities and bank deposits, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in accrued liability for employee severance benefits, net of retirement fund profit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(108)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,442&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,759&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash finance income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(347)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of effects of businesses acquired&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decrease (increase) in trade receivables, prepaid and other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,783&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,297)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decrease (increase) in other non-current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">404&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,027)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in accounts payable and accruals</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">856&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in inventory</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(688)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,849)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,551)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(52,211)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Investing Activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of fixed assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash acquired through merger</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,641&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale and maturity of marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,381&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by investing activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,980&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Financing Activities&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds related to issuance of common shares through offerings, net of issuance costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,127&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds related to issuance of stock for stock-based compensation arrangements, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">376&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by financing activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,503&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase in cash, cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,952&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,909&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of exchange rate on cash, cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash at beginning of the period</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,418&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,584&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash at end of the period</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119,371&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,456&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118,516&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,601&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">855&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">855&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total cash, cash equivalents and restricted cash shown in statement of cash flows</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119,371&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,456&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplementary information on investing and financing activities not involving cash flows&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cashless exercise of warrants and restricted stock units</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares under employee stock purchase plan</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to operating lease right of use assets</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to operating lease liabilities</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest received</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">963&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">973&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of assets acquired</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117,270&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less liabilities assumed</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,827&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net acquired </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111,443&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less cash acquired</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,641&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Merger net of cash acquired</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,802&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Represents an amount less than one thousand</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i6c0fd19f510f41d2bf51ccdb6de7c099_13"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables reconcile non-GAAP financial measures presented in this press release or that may be presented on the Company&#8217;s conference call with analysts and investors. The Company believes that these non-GAAP financial measures provide management, analysts, investors and other users of the Company&#8217;s financial information with meaningful supplemental information regarding the performance of the Company&#8217;s business. These non-GAAP financial measures should not be considered superior to, but rather in addition to, other financial measures prepared by the Company in accordance with GAAP, including the year-to-year results. The Company&#8217;s method of determining these non-GAAP financial measures may be different from other companies&#8217; methods and, therefore, may not be comparable to those used by other companies, and the Company does not recommend the sole use of these non-GAAP measures to assess its financial and earnings performance. For reasons noted above, the Company is presenting certain non-GAAP financial measures for the three months ended March 31, 2021 and March 31, 2020. In order for investors to be able to more easily compare the Company&#8217;s performance across periods, the Company has included comparable reconciliations for the 2020 period in the reconciliation tables below. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of EBITDA and Adjusted EBITDA (non-GAAP)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of Net loss (GAAP) to EBITDA (non-GAAP) and Adjusted EBITDA (non-GAAP) for the three months ended March&#160;31, 2021 and 2020 (in thousands)&#58;</font></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (GAAP)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,550)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,233)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;EBITDA (non-GAAP)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,466)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,105)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share based compensation expense </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,442&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Adjusted EBITDA (non-GAAP)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,024)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,346)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Net Loss and Adjusted Net Loss (non-GAAP)</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide detailed reconciliations of various other income statement data between GAAP and non-GAAP amounts for the three months ended March&#160;31, 2021 and 2020 (in thousands, except per share data)&#58;</font></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss (GAAP)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,550)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,233)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Share based compensation expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,442&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Net Loss (non-GAAP)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,108)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,474)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense (GAAP)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,333&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,953&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Share based compensation expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(458)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(516)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Research and development expense (non-GAAP)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,875&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,437&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense (GAAP)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,616&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,415&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Share based compensation expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,984)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,243)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Selling, general and administrative expense (non-GAAP)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,632&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,172&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Expenses (GAAP)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,949&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,368&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Share based compensation expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,442)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,759)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Total Operating Expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,507&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,609&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Loss (GAAP)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,431)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,889)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Share based compensation expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,442&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Total Operating Loss (non-GAAP)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,989)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,130)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic and diluted (GAAP)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.79)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Share based compensation expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.17&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Net loss per share - basic and diluted (non-GAAP)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.62)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,868&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,627&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mnlo-20210506.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:56529dd1-5759-46c4-b2ac-a07bf551e378,g:904f905f-39e0-450c-8019-d0e9182565ac-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mnlo="http://www.menlotherapeutics.com/20210506" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.menlotherapeutics.com/20210506">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlo-20210506_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlo-20210506_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlo-20210506_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlo-20210506_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument">
        <link:definition>0001001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>mnlo-20210506_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:56529dd1-5759-46c4-b2ac-a07bf551e378,g:904f905f-39e0-450c-8019-d0e9182565ac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="mnlo-20210506.xsd#DocumentandEntityInformationDocument"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>mnlo-20210506_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:56529dd1-5759-46c4-b2ac-a07bf551e378,g:904f905f-39e0-450c-8019-d0e9182565ac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="mnlo-20210506.xsd#DocumentandEntityInformationDocument"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument" xlink:type="extended" id="i32c34264135248508aa5ccfdda6951f7_DocumentandEntityInformationDocument"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>mnlo-20210506_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:56529dd1-5759-46c4-b2ac-a07bf551e378,g:904f905f-39e0-450c-8019-d0e9182565ac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_WrittenCommunications_f7d32a1f-1ecb-478a-a353-31ad88fea142_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_f747caa4-9659-4a21-ba53-c0cdda27e64a_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8738f15c-2da8-492f-a755-f29e1ad29a32_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5f6aaabc-7190-45a1-8721-4c9d18f54fd9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_eb93ed2d-bc46-4f37-ac6b-566a6feb4c24_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a6cbea80-23a6-4501-a198-37dc3100a937_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1c060f34-1d48-4ac8-b4a3-8756b718b831_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d64cd8d5-2181-473f-9337-6947bfbbe8dc_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_7f3e4921-d7a7-44b8-ab99-dd2d31057a0a_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e20b3baf-9e02-4bae-89f0-2cf8e9bb8577_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_aeee2d2e-b70f-4463-ae69-13f12ddc1f0f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c2387bb3-2035-4c18-b1fd-a91187d5a10f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e0f0b13b-b66f-40ea-a478-85e50701de77_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_b7d31853-fab9-4568-9fc1-b1da2dad41b2_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_977dd24f-cd10-4b33-aca2-946cd9362cee_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3e7aedd2-c971-4efb-a648-3a3662eae735_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_af9c44c4-0a62-44ce-8a85-86350eec73cd_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c68a2660-8e60-42a1-8fdc-d76ef7c32ae3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a4f1fbb7-99da-4c05-ab18-265a7db6eed8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5d1c732a-8a7d-4c14-8e1d-53df3d5a4970_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_6a60d382-00d5-4f83-9c93-1bffaf118d68_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_138e6327-13a5-4b1e-ae91-2e0d46fd09a1_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_1abd94ec-3e78-4170-acb1-8ee704bc85a0_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b8b3ee24-ce8a-4cfe-88d5-5e80203e147d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>mnlo-20210506_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:56529dd1-5759-46c4-b2ac-a07bf551e378,g:904f905f-39e0-450c-8019-d0e9182565ac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="mnlo-20210506.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6b7f6c0d-b199-40a4-ae9e-9d3868c99c0c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_DocumentType_6b7f6c0d-b199-40a4-ae9e-9d3868c99c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5eff803e-f271-4714-8b3c-01bb3b1cfdc6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_DocumentPeriodEndDate_5eff803e-f271-4714-8b3c-01bb3b1cfdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f54dc21f-977a-4481-b1d3-5f2fcaad1219" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_EntityRegistrantName_f54dc21f-977a-4481-b1d3-5f2fcaad1219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_991f932b-fc10-486c-90ba-d5a115109e57" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_EntityCentralIndexKey_991f932b-fc10-486c-90ba-d5a115109e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ed5543fa-7f57-47d0-9883-156784612bd6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_AmendmentFlag_ed5543fa-7f57-47d0-9883-156784612bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_afb72dc3-6e67-4ad9-ab6b-f0a69a676796" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_afb72dc3-6e67-4ad9-ab6b-f0a69a676796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8725122a-a16a-47ce-959c-5cceed85e790" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_EntityFileNumber_8725122a-a16a-47ce-959c-5cceed85e790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c8489411-a60e-48f7-90fe-9540fa1f26da" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_EntityTaxIdentificationNumber_c8489411-a60e-48f7-90fe-9540fa1f26da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d0ed67b5-e021-4ba7-bbc3-6d7a6d79ae75" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_EntityAddressAddressLine1_d0ed67b5-e021-4ba7-bbc3-6d7a6d79ae75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e791e567-1a8c-456b-af59-e8512fc68a95" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_EntityAddressCityOrTown_e791e567-1a8c-456b-af59-e8512fc68a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_26e37f31-65ce-437d-a698-514333ec0459" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_EntityAddressStateOrProvince_26e37f31-65ce-437d-a698-514333ec0459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_528727b8-c53e-4dfe-aee0-76b7f225b1e2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_EntityAddressPostalZipCode_528727b8-c53e-4dfe-aee0-76b7f225b1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4befaa34-dae0-4930-b345-d078b528a087" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_CityAreaCode_4befaa34-dae0-4930-b345-d078b528a087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ec0e16c9-5e51-4d88-ab32-1f32d0047275" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_LocalPhoneNumber_ec0e16c9-5e51-4d88-ab32-1f32d0047275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_9e5286ca-f010-4195-8eff-639bde48202e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_WrittenCommunications_9e5286ca-f010-4195-8eff-639bde48202e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_254d53f1-8ff0-463e-8315-32afdcc4203a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_SolicitingMaterial_254d53f1-8ff0-463e-8315-32afdcc4203a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_1c1c4df3-4999-4ae4-9515-2377ff21dc14" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_PreCommencementTenderOffer_1c1c4df3-4999-4ae4-9515-2377ff21dc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_41ba1f46-894e-40cc-a8b0-ab8dbf27f265" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_41ba1f46-894e-40cc-a8b0-ab8dbf27f265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_edbff881-1251-419a-8343-717d0d7503cf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_Security12bTitle_edbff881-1251-419a-8343-717d0d7503cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3a555740-68e9-4983-af48-a8c667f6d2b7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_TradingSymbol_3a555740-68e9-4983-af48-a8c667f6d2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a8125f0b-3e77-4c99-9997-f592b896fcef" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_SecurityExchangeName_a8125f0b-3e77-4c99-9997-f592b896fcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8b105151-7f69-4078-ad76-6a1d5931271f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_EntityEmergingGrowthCompany_8b105151-7f69-4078-ad76-6a1d5931271f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_24bee36e-a13f-4532-900a-990f7aa2b115" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7aace04-344e-46e7-918b-2a89b84e810f" xlink:to="loc_dei_EntityExTransitionPeriod_24bee36e-a13f-4532-900a-990f7aa2b115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image1.jpg
<TEXT>
begin 644 image1.jpg
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MMO:CVG9L1Y:;;=B6"[3G YT%0%N1]DTW)QJK;],4M0)FPI'J&2")<K9GVX6
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ME'XI6I+[H3EUH*3M3QR EM1A:$P:* #6XAZ*1M=@U"?U%UH4.B&MN/J98X"
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MY+A["&J](W$\64W.M9W["M=%@&EV]0$YIMUIUP+E6XS]1+<L<1+L=%;F[!P
MF@[B2-J%QHI6EYKIP$<PX:)"M6<H\K(N 0Z^;8* V0+'G;6R<D,N;5UY/@E'
M0B"AL9BT9\H( 1*LFR_Q041)RBAP$F&N"R"7R4DJRGOT3(\[)'H9?S<'O:AY
M"!<6D(F9?:)<BHX).WG'E?XW7_92(J66OQG!0YM$J1;(N1>!G/M  *%8T['T
M7H17/H2.I?>(+TX@^RZ$EOX%#4]?BEKW*/45H!>C:Y HW^H3_X!6[R"4IXS
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M10]+[ <"*X&#9RHW:8Q&<&&8O0/S_ZJ!=J/M,;"P0!"WJJ%UC-7)YJ7WX]O
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M_D'&&H];)=3NED#3C)G#E2@14\CRNP:C.E$5F@1+B5_B'0]L7:UID+-J."1
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MMHWL%WNV8Y:K'M9LFI0?]*'UPPS9]H"$1D*D-2B!A!W+)46R^PQXC"/KU)9
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MC+ ?;3^L1J'W D>Y9X&$ TZ6>UW#U!:!<3C$N5 SBG<[.-6L?_'Y4P*2RI\
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M\<A')7CLBUH\\GD='ONB&D]^7HKDCW+%VI6^MC1>ZW26&JF I#U"B%%*S"K
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MT[?+YE"%F1?*%H\E<Z]"ON=B',B\"MNS;@$*UXF),TVS600IAG18C 47 A3
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M\_V$_N![3L%8RA/J97YG?CSD62.B.=_YC).,>9_@29/K+B[=T^VA#NBHUJ!
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M>W\0^6=:4-4R+%&G7F6(PFA%]<"R^>JPS+-MV'*T K_:7X ]9\ZBK&U  -4
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M]M0E7XPJ;/"5:J0V*%M^PU6LVIF+5?X2O))6C/B$?,0G'\-K*<4XUCP@$8;
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M;/"585WR"? ]\>Q3,S]!);'T,M[P%\MFV-+/9PG!8:D! M!:_U$L3RU'%11
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M,J9RN+8-6=7-N!)4IY1&+J"62)#9D)2%#4G9WIL8.4A-GCD>M#+Y!)+J1AQ
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MZXEZJ&D;P+KD(_!5]XA\*K-&*P3)C_-.XXWTHQ+A];HH4"J=IL0RV+ Z/7&
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MYIW%FN1"B6@8BM->R#?;2AHN!R\7IU<BX0J0T0JDGX\@\V(011=Z)9PF.,M
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MHB4$"4"BHY@2C1<ZNPQ"ZE/!K!9+Y6T@Q>+I**[.I"[9&'#]AI?:ZLHU4G3
M<$1:;0%V*B**7U'=<1O+""=R0[)_"IV5=L-QEJ XH]%P40\5$R;XL4X8:SB]
MDKS#Y5A;$_W++2E91B($2%@'PJ-3C:K?^_: 5>J5L\OL?KCX+Z+Z9!USRE<(
M2U=(>1V1_6+UMQ/;TQ-52!'L.G_SD(_08CX%(;O\99Z_ $AH'HJ@*H16A!J"
M.I^ .RL[QFG_4"'4Z+5V:1B>YFA?O"QTM'3RXU6<QZ6V.F;DDE^*<Y54.M\
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:S_]V/O\/<G-AD)77%D@     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>mnlo-20210506_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mnlo-20210506.xsd" xlink:type="simple"/>
    <context id="i97d13bde7dea4028b80263a284e93354_D20210506-20210506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2021-05-06</startDate>
            <endDate>2021-05-06</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV80L2ZyYWc6MzU5Yjc2NzhlNWE4NGRhN2I0NzlmODliNTFhNmI4MWMvdGFibGU6YmFlNzEwMjVjNjUyNGNmNWFjMjQwNzVlMTg2Zjg5NTYvdGFibGVyYW5nZTpiYWU3MTAyNWM2NTI0Y2Y1YWMyNDA3NWUxODZmODk1Nl8wLTEtMS0xLTA_6570c9cd-5c02-437e-8881-3abc21ab68e8">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV80L2ZyYWc6MzU5Yjc2NzhlNWE4NGRhN2I0NzlmODliNTFhNmI4MWMvdGFibGU6YmFlNzEwMjVjNjUyNGNmNWFjMjQwNzVlMTg2Zjg5NTYvdGFibGVyYW5nZTpiYWU3MTAyNWM2NTI0Y2Y1YWMyNDA3NWUxODZmODk1Nl8xLTEtMS0xLTA_8193b06b-ae45-4276-b83a-ee4ef1a3c8aa">0001566044</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODA1_07b8748a-e245-42b2-bf4b-b94f717e0874">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF80NDA_2b2e56bd-3459-4091-ad08-184bf7cf4e14">2021-05-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xNzk4_461e8cdf-fef4-432d-ac03-523cffa12b9d">VYNE Therapeutics Inc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6NGU2Mjc3NmY0OTQyNGUxMmFlMGYzOTU4MzgwNzg1N2MvdGFibGVyYW5nZTo0ZTYyNzc2ZjQ5NDI0ZTEyYWUwZjM5NTgzODA3ODU3Y18wLTAtMS0xLTA_40b8fbee-1dce-43f5-b4ea-8e9df114659a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6NGU2Mjc3NmY0OTQyNGUxMmFlMGYzOTU4MzgwNzg1N2MvdGFibGVyYW5nZTo0ZTYyNzc2ZjQ5NDI0ZTEyYWUwZjM5NTgzODA3ODU3Y18wLTEtMS0xLTA_7632c04f-5b0c-4820-83c8-61c15c660bfe">001-38356</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6NGU2Mjc3NmY0OTQyNGUxMmFlMGYzOTU4MzgwNzg1N2MvdGFibGVyYW5nZTo0ZTYyNzc2ZjQ5NDI0ZTEyYWUwZjM5NTgzODA3ODU3Y18wLTItMS0xLTA_92d7f462-c72a-415f-947e-504473fa0426">45-3757789</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODA2_3df3d713-fa8b-4fa6-9908-4bda7907e830">520 U.S. Highway 22, Suite 204</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xNzk5_67553aed-da69-4bb7-8ef7-0d45fede1fde">Bridgewater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODAw_f7583db5-fd68-4f14-97a0-9e2bf40dba97">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODA3_6fc95c90-75fd-4479-a4e8-2f060686779e">08807</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODAx_15ffd636-c916-4d03-bb42-90726cb8bf91">800</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODAy_8cdd7185-3568-4e99-bfa3-7c3a296097e0">775-7936</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6YjU2ZGRkYWJlYzE2NDkwMWIxODBlNDY1ZTIzNzAzZjgvdGFibGVyYW5nZTpiNTZkZGRhYmVjMTY0OTAxYjE4MGU0NjVlMjM3MDNmOF8wLTEtMS0xLTA_2f4e0088-ba3d-40e8-9d48-d3ceb1686c15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6YjU2ZGRkYWJlYzE2NDkwMWIxODBlNDY1ZTIzNzAzZjgvdGFibGVyYW5nZTpiNTZkZGRhYmVjMTY0OTAxYjE4MGU0NjVlMjM3MDNmOF8yLTEtMS0xLTA_224454f6-82e9-439e-88d7-cf2c5f7da4b1">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6YjU2ZGRkYWJlYzE2NDkwMWIxODBlNDY1ZTIzNzAzZjgvdGFibGVyYW5nZTpiNTZkZGRhYmVjMTY0OTAxYjE4MGU0NjVlMjM3MDNmOF80LTEtMS0xLTA_5cdb1466-ca39-481e-96a3-9b0cab5fb4d1">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6YjU2ZGRkYWJlYzE2NDkwMWIxODBlNDY1ZTIzNzAzZjgvdGFibGVyYW5nZTpiNTZkZGRhYmVjMTY0OTAxYjE4MGU0NjVlMjM3MDNmOF82LTEtMS0xLTA_383bfa52-f5d1-4a02-a25f-bad369599a88">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6MDNjOTgxMmU3ODgxNGQ1ZDhkMjU1NTcxN2Y0OTFjMWEvdGFibGVyYW5nZTowM2M5ODEyZTc4ODE0ZDVkOGQyNTU1NzE3ZjQ5MWMxYV8xLTAtMS0xLTA_7504efec-1468-4cb1-a8a5-8879c7b291ad">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6MDNjOTgxMmU3ODgxNGQ1ZDhkMjU1NTcxN2Y0OTFjMWEvdGFibGVyYW5nZTowM2M5ODEyZTc4ODE0ZDVkOGQyNTU1NzE3ZjQ5MWMxYV8xLTItMS0xLTA_937191c1-096a-466d-891e-5a9de2965788">VYNE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGFibGU6MDNjOTgxMmU3ODgxNGQ1ZDhkMjU1NTcxN2Y0OTFjMWEvdGFibGVyYW5nZTowM2M5ODEyZTc4ODE0ZDVkOGQyNTU1NzE3ZjQ5MWMxYV8xLTQtMS0xLTA_ee7f2207-fea9-4615-91f7-168b827c3fd8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODA4_2629dcfb-9712-40da-8338-98577d9171b3">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xL2ZyYWc6MmEwMWE5ZTdlOTcyNDlhZmEzZWFhY2MxY2I5OGFlMzAvdGV4dHJlZ2lvbjoyYTAxYTllN2U5NzI0OWFmYTNlYWFjYzFjYjk4YWUzMF8xODAz_efc43d24-85f7-4391-86a1-544db63dc1bd">true</dei:EntityExTransitionPeriod>
    <dei:DocumentPeriodEndDate
      contextRef="i97d13bde7dea4028b80263a284e93354_D20210506-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOjAwZmVlZGFjMjAyZDQ3OWM4MTQ5ZWM1ZDkxNjg0NTI5L3NlYzowMGZlZWRhYzIwMmQ0NzljODE0OWVjNWQ5MTY4NDUyOV8xMy9mcmFnOjczNWQ5NjI4NTI0ODRlNjQ4NmExYjA5ZjA5ZjBiMmFiL3RhYmxlOjdiNzU1NjM1ODE1NDQxZjFiYzIzM2MwYmY3ZTAyNjE1L3RhYmxlcmFuZ2U6N2I3NTU2MzU4MTU0NDFmMWJjMjMzYzBiZjdlMDI2MTVfMi0wLTEtMS0w_2b2e56bd-3459-4091-ad08-184bf7cf4e14">2021-05-06</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139931883339336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>May 06, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  06,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VYNE Therapeutics Inc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001566044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-3757789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">520 U.S. Highway 22, Suite 204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bridgewater<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">775-7936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VYNE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M'LBJP]'Z<&-DDAUGE]+ X3B[W' &"].^ ,]74IK3C3TAYS]P#+\#4$L#!!0
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MX_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0
M   ( %<YIE('04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ 5SFF4I_X/4WO    *P(  !$
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M;',O+G)E;'-02P$"% ,4    " !7.:92'#AEZC\!   \ @  #P
M    @ %G$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 5SFF4B0>FZ*M
M    ^ $  !H              ( !TQ$  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ 5SFF4F60>9(9 0  SP,  !,
M ( !N!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @   A0
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mnlo-20210506.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="mnlo-20210506.htm">mnlo-20210506.htm</File>
    <File>mnlo-20210506.xsd</File>
    <File>mnlo-20210506_cal.xml</File>
    <File>mnlo-20210506_def.xml</File>
    <File>mnlo-20210506_lab.xml</File>
    <File>mnlo-20210506_pre.xml</File>
    <File>vyne-2021506q1x2021exx991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mnlo-20210506.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "mnlo-20210506_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mnlo-20210506_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mnlo-20210506.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mnlo-20210506_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mnlo-20210506_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mnlo-20210506.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mnlo",
   "nsuri": "http://www.menlotherapeutics.com/20210506",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20210506.htm",
      "contextRef": "i97d13bde7dea4028b80263a284e93354_D20210506-20210506",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information Document",
     "role": "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument",
     "shortName": "Document and Entity Information Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20210506.htm",
      "contextRef": "i97d13bde7dea4028b80263a284e93354_D20210506-20210506",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001566044-21-000024-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001566044-21-000024-xbrl.zip
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MF@WKHB#\7R4OM_<^'1/@*">I0>WB<]'(K:8XP9@$_B"JNS"#+($6,N($;%G
MB1,@'+MQ$)!QRNK+#^^6HJH0R3BO]"XDR0"(<^(LB\,ZIPUTP,QW25!VDO=7
M/+XFNRH4I&<P01E=]EP^KN:/:AF]_<PTJJ9P]V.A*EX]J^5M)\L"Y>S)XZR2
MUX-1\6GZ4)$K-P9>#D4<9RB- Y^B7X'8=^7#+![7I?4G8T*I'PWJ A+SQJ][
MK^53M&DYBTGCC4&==YN6A!.W+ ZTQDF==\;[\X#IL$="/YC7_]/Q0X .FTW1
M21R2Z#^[*>A(H, EOE<43/T%JXL&]))_G1;3H$,[^2*6TR)*?%*[=JO3;*#3
MSGZG>;K.1O<PT$M0>]H\Z)ZT.JWF*=JW&ZCYS\&?^_91$QVT+:MU>MIJVR\X
M!.%!0S@CZ1!8)XNC7=2H'E3!VE$5\TZR5]A&>PZVT1XTB//G^[<U,_- %CUL
MGUCH"36ZI55=V"4OJ<C-KA2Y$!2RLZ;:[]"@W7%!H0J&_;"YZ)\=#GN2->M)
M+;5]=!A8BWU0RCXK],^_@KX47#JC>-[K[,]ZG2"PI:YJ+UK0SV'8ZP MH-3U
M%O WNE! <5M8AP8H:/OB.9C[AJX8H'Y)N3;F2-CQ% <[IN+IHLX$>%K9,_#?
MM]6PET*&5[FG<CC;%M $U#]IVAUTTOS8/NEL/<9_G"3IA$09RF)TRESNND"B
MC.($B>H._1W%'LJ&;.N' :1/$C_SH<7FS!V"G<+0OIMQ\L$D4EX=%W&UGA-_
MPL9QDJ&=Y7=&0+%G:8;8)7=7)OEC!NOTI$X8"KV'T.*0DOD<2&#1)IC_F%L?
MS<(F^;GP7@##_!SPG:F:0[&L<+>O8(J84,' HJ$XGNYZ"A,![BTR_^U741/>
M:;NY]_C!V/^F7FW+S$C*@Z;FR7UE)VS@I]SMG-GPY.?:<3-[<:&<*YK(#)=Z
MV&.>@A59HIBX@HQ5278]CXB28]+*WN>>W42=(4O(F$W ^$]1*W)O[KOJULNX
MG>:,@$CC7,!%07*U^HBD*!TSE_N?*/(CY&<I B$(DB'Y?6MVS>O!DU?M@Y*E
MJB3+#_)!;4NSRF,\9G>YQY9^+FD\0QN]5C=G/?0I#=@+[>6G5-=X@)1[D3,V
M3N)+#A?K^EHA/  "XP2TQSQ:><I+'\23*$OF!S%]G;*D"+O81UW)&KFR'?:$
M=N?3'+[/K!#*'/46[4Y7L1:#J;T8B+9DW0B[Q$*_TYO;"U?JCSZI=J,%WYOP
MK#OMCRS5[@P68-7+[497[HD\H+9_%791!,?P',:P2%T&8LA3L:,P@@UF4D\4
M%4TU">CT+"!34)[OU/C*'?#&W/<I/H=^P*!U!Y#YC5'O9]3K^*"NR9(K*!Y6
M'<'%BB$)V)!= VNB*ZJNI@F.QWAX2\2R(:O:&Z=^*Z=VR*Q5A@;='&G?V/;!
M;-NZ8EM3HKJG:!)V=8E@150];"HZPZJ@*+KL$4&1M,J>HF)95W7=,+_(MS^4
M'K&32V[NKHLS,'#0:)+X*?5S/UX>;@5#P5^5]+__<'MXYR .0S]-ER/FP@$5
MV^P''&SKY!0UPW$0SUF2#W<=7C8._,'17G6+/*!/#LW[E"8L3<O_CH$ \57"
M\C<%J:1SF7HRU4495M%PL.(1#9NF8&#%H40W!9T9LE#94R4!=:NG5?0G+-&4
MS)$D[:+3B0_8(PD;CA%MN2OEN9CK #ZVDTX\C7XRUK(7%^JYIJNJ3!C%E&@F
M,)2C@T7DZ5B@BNHQRD0/+,V]/Q*?#M@4Q%ARDX]VGS2L\3 [N5S)7,ZVDX]0
MTL]/Y_Y4RPE(,3WW=-60J:-BCVJ #YZH8%,G C:9Y'B*0!UBZI4]OD/_8DG*
MYC=7\RF/&JRMU<<85C7H^^-7Z\KXII62SS7/-577%+"N>A2#CFQBHC #2YZ@
M"9JAZ;K)S3S#$/17!]T[Y2)S%_@X@;WHCTF V(RYD\R_Y)YQT(58NLO5WF#"
M53L$G( X*SS(%[Y58>"=)]PR7#;M)XS\G)MD=@Y6) "9K&'7%#6L4$'&CJ-(
M&'0>27,=P_%,L;)G",+-+?($P?;K53F.P=+X.(RCU^S@^J:5F9\;+@6-U !S
M7N6"AIDF=CPB8]V%>30UP=09J*2ZKF+=E.]V4FTM@EW';7_[U9!$_5V*,A:P
M,5]U%.7+O@I?!#8I\-B7\.NNH6TZ<OT6 GQ "/"&0'AR3E$VGR4;,O>"G[]"
M9 PZ*H@[[NQQXAER6!!/D9\?SD*'H-,69TH,_'?QP?,#SCI^"GR4L8@RR@]X
MI7XX"3(2L7B2!G.4DLQ/O7G>1EDA=F#Y"T]"<?)K-<P\@7821*+Y\ID7!T &
MK\<U:)^[8-+Z [EMVV*J7XI@"E5#^OZQ3[6JZU_J\^M:->&AH'W/B.K:S8$7
M<J*=0>N\A_2K-Y3P+&%7?EW1(; K,MBEJW+]+/$SV(C<5SF)2F==^BJ%>WF[
M;=25^D<G%[VSOZ#?IF0W+J"-%@CP/P*[T1/[G=;"7NPO^J/!K=MM=J=_ 76'
MO?#S".@1VEQ!&#45ZZ@KV*//@36R9*MAA^W#]>B5Y"E, *L%.T0&LT8 B\:D
MBH&I[#)'!+O&%=7*WF^_FKJBO/N^L:N >;<@YID<P9LYN>0G&,8J0Z'QRG'>
MDPF@JR*I)6YSP%XY)LM/Q^Z(.CHX/$&2+%2AX :O\:T;2L87;BA]!6!\;=$W
MZ'H^Z#J- ]\%IHD&%G?2^21XPZW[<&N^AEN2HJB*IV%#8B969)/?MZ8Z=CW)
M53V=$L41?Q;<NF8F%);<= NT"A565 @6I>+S-8*MG>XO\:LH(RF@V^1UWG#L
M#<<VX-C'A''UB]\LSV^E<;,H:7O>*W6R/"N>":MXIKK4$15-PRZ1 <\,D6%3
M(S(V'<$ECNHY"OUI\ R8"KLK7%5@T3U:V1+@*)9VG-\?"W%%K3>0>P.Y^T&N
ME:83EKQ!W2.@3EJ%.MF0'8^H$O94*F*%"!(FDNJ!!4IES51-DQC&&]3=#W4R
MP\J.^UBH*VM]_6FF%_+;KIC9A?N4)8RN34UYU;:<'8[G2Y\JS,1M%^J6^4J_
M>*,#'FI?YRS]LLM351]V3^3')O:[>G8?+$8+YGC^>%G.@AV>HJZX_.P.D1N0
M-'T$LCZ%5O&RTY$03FT>V3N=ATX<[*2/.>CZ(TU(CK9V>2$R9P]62I3B\'.$
MID,??KU&X<<<!5])JK2>;DE8R:OTX#F"9EZ(8Y[PN$(IZ>:BY.3;]!6KEZ#^
MC=J=P<P*NW*[,9C91Y^ GN&%->J*=L>=V1)7&X'NL^;-BPU32[)4H&G>[[@*
MIZW?^'S1/OHTMSM0=]&4^84'ZPSZY32N7!S354%A'G,QF-,&5EQ'Q,0@*C8,
MW71U1S)%0BM[7*$'5C[-8O=B%_UO+II%-"8)NB3!Y%ONDST "]XVP;V;H$3D
M HS?=L #=L#*U1Y9%TW1%;%@:@0KFD:Q88H,J\2D3#(U5><&%K_!_\;F+\+F
M-ST/7,#>/BN]E -+@^[5)J1X[IWPZ6HG,*9[DB3HV&.$9PT756R*GHY%#19*
MTEW9H[ 3.F BVB2EY-]"'B"+)!<L0\?'!_??>MMNJ[D54>Y&8,B9(S<_^01D
M78 &Q_*K;3<.(_DI A(9#'7 @TF#))YF0QX.'_,#2B1%E'G019X/HXB$"^K2
MQKX1!B^21,EHAYOC^KL\&KXL[.>9-,8\DP:_9;?BTI <7$:G;K>Z*0=547;9
M!W=OW&AAI:LJ:FX>6%%\N;+/YM1\\IP%RSS?63)AM\_U+R?C*)^+@V(J7B6\
M?-/)6.5<TB23NIZ#35V4L")0@@U9-K!IJ+I.35$7';ET1VIWNR.W\[!CR_O"
MAN;G83>B@W_KE.(0]CX+F,M?XQ#%N;=MDK*\%+!K>1:2Y^KW\V..1<YDSHMY
M7\&<=YZ__H'C2 1C@R<)N_13J >(0B*7QZR)Z_)T&;PPS]=/24+3XA0D_:*K
M3]XA5ZZ^592HHI]N4\\Z5ZM0I([[^7;TXIQYKB)32<&&"K)>D4T1&QH1L:HH
MU-%DZHH._1X[^M7XCY\QA[9T9PYM\9MS:*^F0Q_'!9?7$Q80?DGI5H+T:_IR
MPH3K*L0!.B;9[2KWY51_;&)WO;*L,TRN[:<!PT["R 4F'N@E=1),R3RMU)XJ
M^_LJWTK/((DV.Q1;&0N15!4D=,+229#E=\W:("C*&!? /3J\D@0',4@F_N#N
M#'+//:S-4-^.T,WDD[MH8VZ\*FC7Z03D& &1QN_: >,R D*41!%(/3>_6@#3
M<BT.DW*BN!CEHNW?29Y]#A7B%FP4=XADL>BTRON[T3#HO@[CS7J3)/+3(>^;
MJ]%#W_$S9)I5<=MGEX_)CZ[>_\/-CFL^6NKW_*8&,O#?.0NMC@Z1+",N'S8L
M!>-7-88D"'+]Q6%@RH!:1!&_+23E=SL8S3^+[_()!VT#\(+E;'J5P]?88.QL
M,DMV^423L%BH'5ZA[&:U<-G;[[M7F4:FH ^A=.*,H#^NY?"*@4\</RBZRCLG
MV9*>O.)U(A+H"M2XJQ=]\,GBVE9Y">7.\\JEH;9*<M[P365JEX<!V+A(C)A/
MI,.5OYSE^+T7L)=AWD#% R+*Q(GN.C7I!!B6E 1M8+T'OBQ#J&S@5^Y&P2 R
M$^)F]702 O_.WVT1\IE5 ?;H-<#E5]]YP#]=9=MT"S9DWF+=ST -<1]R\8[^
M?D7]RQ-_+YI<WZYB)5)L0$D.%]Q:>=!J;.&UJR^I@J)2597O?^_*D*N2JC]Q
M''W3Z9UGBI)N.KU3D$:96Z:!JN<8RTM5]I9RR(ZKW__$TI:.N<%2-_''>9JL
M^\]1FD]XCO*'8;'*'E=DGI"#KDR)#>/RO!=AH_=DHU O\?K=BQ.(BE>O7<ZA
M!E>]54'[5YSQ3VPV,TVQ.LS"_&#?M2J^BVBNGX&I@$HK 6"!W+3<[MXLHO*V
M6QZR6T1!^:'@EI]3 &K01P)*>(M'16$K\(PL#9(1E&?EVV&APR@MWZ\+:C97
MW%NY@H'R]_#2\E42CSGQ^>2>EF65QR19^#H?C"AO@Q-F6_)DG+:.[/U.]^0+
M+WO;CLC%ZCMTBF#$OQ,_*4VFQUOANYLB&G0"AJM+)CP*D;L2BE>_\"[!MDUA
ML>!!7*3^=QC8O!XW;GE#N30H"W!K81)!G;PY,LF&<0(#I3^B]:"855U_F)K_
MF&:EJJ%\_U85I2KHSY.U07M21>Q)$:%P5O[9/-G_V.QV6@>GJ&4?/#)N]EUW
M?G4[M**?4X'BKYFJO[WX:CV(:<W-T T/H_;(7?!G]JBE\#=(MQLG@3WZI-AA
M<]8;[:O]_.\/WPH/_6.97XR:!>T1]>U%5[1'E@CMBW;CTZP_.O2AWX4E6=->
MV)/[_*W4HZ:XK -]3?I25[.EEFQWNI*UZ,)8NH+=. RML[]@C-:BM_C#[X]H
M8#5:DM7Y[%F^L,SK,7WX6[/0?2_,^C&4Z#_F]1]G1#E(UM(:LB;9G* _29*Z
MPZ_)QOY]D?'^2.\#Y_4YSGENGM2U">5*_<'09QXZ9@,2H':> S/)W?5'+ )+
MC(<I)U'*@A_)L*HY,9W#?\,L#/;^'U!+ P04    " !7.:92CG,OJZ4"  #S
M"0  $0   &UN;&\M,C R,3 U,#8N>'-DW5;?;]HP$'[GK_#R/"=.("V)"I76
MKE(EMDE=J_9M,LX%K"9V9CN%_O=U0C((I1N9]K!-0L+<W??=?7?^P=GY.L_0
M$RC-I9@XODL<!(+)A(O%Q+F[O<)CYWPZ&)R]P_CAP\T,74I6YB ,NE! #21H
MQ<T2W2>@'U&J9([NI7KD3Q3C:0VZD,6SXHNE00$)_'VOBL.3,(B2Q,?A:1CA
MT0D;X7E &:;D=)Z&H0_#T_'[11R141J1,,7#" @>A83A,?$CG!"(_'%@62RF
M(EWK6+,EY!1984+':SUQEL84L>>M5BMW-72E6G@!(;[W\&GVM0YUFMB,B\=.
M]'JNLC9^Z%7N.=70AN<BDYUPVY=,FB4H6D!I.-,ND[E7Z28A.7$0-4;Q>6G@
M2JK\$E):9F;BE.)[23.><DAL[S.HNML)V'$;JA9@/M,<=$$9],D^'2!4=8?G
MA50&B8,<37O\*(J\=:7709MNSB2CIMXB;[:GCL?5$OL!'OKN6B>.=U3:+A$7
MVE#!H$]N^PNWN#]1PW;6_6IH<?UKJ,DT,'<AG[P$N"6U^YOXEN%P$?HM4+7
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MW;GTO8$(A&<)!E!W:;FN<R_8@^A;'+8G\FT^93QBW3]]U^J>-W7&Q^P:KHC
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M(=HZGN7&ML!S!)\!U\;RP,!.PX&)DE/H^@]X;B8"1> I'@]@YQ.XT>ESP-/
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M3";J^9YXX3LW7I31K/>:G4T7E6_8WD;#OB$X!.L6J##O;6/RC1GS!DA$QD5
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M-F.5C'%F\4D8NT+1#& XT:P TR%@J65.  Z!B!IBL*JTKX09MS?%F<!)X$$
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MEK,!_ @>%0%)AHDD-F>$\?$>>D\))A[%IY'9R *5:QPF-P;BWO^*S"Z@*06
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M*ZO :CFJI1>UEVME%-@_]2F91:!H#=,VLQ5D@[V18FF2;F$!V7ON4C59](2
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MPBS:U-D['[>4AYB_!N^$*?*^?R^T>3BE!YC**0%WY@"ZQS9T0 <:.5D@X/
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M^^G T]"U=F-+D?^ \'R\*V71._&]Z?OV%/X916/WI_\/4$L! A0#%     @
M5SFF4N2WU&.E%   XH4  !$              ( !     &UN;&\M,C R,3 U
M,#8N:'1M4$L! A0#%     @ 5SFF4HYS+ZNE @  \PD  !$
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M4$L! A0#%     @ 5SFF4J^WN #W!@  \C,  !4              ( !S28
M &UN;&\M,C R,3 U,#9?<')E+GAM;%!+ 0(4 Q0    ( %<YIE)KTG<NX#H
M 'Q. P =              "  ?<M  !V>6YE+3(P,C$U,#9Q,7@R,#(Q97AX
=.3DQ+FAT;5!+!08     !P ' -4!   2:0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
